Brief: Elite reports on SequestOx FDA end-of-review meeting
23/01/2017 13:18
Jan 23 (Reuters) - Elite Pharmaceuticals Inc ELTP.PK
* Elite reports on SequestOx FDA end-of-review meeting
* Elite Pharmaceuticals -To proceed immediately to complete
in vitro and in vivo bridging studies required and expects to
resubmit SequestOx application later this year
* Elite Pharmaceuticals - FDA meeting minutes support plan
to address issues cited in July 14 complete response letter by
modifying SequestOx formulation
Source text for Eikon: ID:nGNXNOARNa
Further company coverage: ELTP.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Elite Pharmaceuticals
See all newsBrief: Elite Pharmaceuticals Receives Approval From FDA On May 16, For A Generic Version Of Methotrexate Sodium 2.5 Mg Tablets
Brief: Lannett Enters Into Distribution Agreement For Dantrolene Capsules
Brief: Lannett Enters Into Distribution Agreement For Generic Adderall
Brief: Elite Pharmaceuticals Gets FDA Approval For Generic Version Of Allergan's Pain Treatment Tablets
Brief: Elite Pharmaceuticals Files ANDA For Codeine And Acetaminophen Combo